Siegfried Holding

Siegfried Holding is a Swiss contract development and manufacturing organization (CDMO) — the outsourced production partner for Big Pharma's active pharmaceutical ingredients (APIs) and finished dosage forms. Headquartered in Zofingen, founded 1873 by Samuel Benoni Siegfried, the company runs nine production sites across Switzerland, Germany, Spain, the US, Malta, and China. The 2025 customer list reads like a Top-20 Big Pharma directory: Novartis, Pfizer, Bayer, Roche, AstraZeneca, Sanofi, Eli Lilly. Revenue 1.33 billion CHF FY2025 (5.0 percent year-over-year), operating margin 18.8 percent, ROE 16 percent, earnings growth 16 percent — these are healthy specialty-pharma economics.

At 78.90 CHF the stock sits at the 31.4th percentile of its 52-week range (low 68.50, high 101.60), trading below the 200-day moving average of 80.96 and roughly in line with the 50-day at 78.43. Trailing P/E 20.6, forward P/E 17.4, P/S 2.6, EV/EBITDA 12.9. Free cash flow was minus 21 million CHF in 2025 — capex-heavy expansion phase (the Evionnaz Switzerland facility ramp and the El Masnou Spain capacity addition combined for 180 to 220 million CHF capex in 2025).

The CDMO end-market is one of the structurally healthiest pharma sub-sectors of this decade. Big Pharma has shifted from build-internally to outsource-to-experts for everything from small-molecule API synthesis to peptide injection-line filling (the GLP-1 cartridge demand specifically). McKinsey and IQVIA both project 8 to 10 percent CAGR for the global CDMO market through 2030. Siegfried captures three Big Tailwinds: (1) GLP-1 and obesity drug fill-finish capacity demand, (2) Pfizer-and-AstraZeneca antibiotic and respiratory franchise consolidation that requires high-volume API supply, (3) US Inflation Reduction Act geographic-diversification away from China sourcing.

Analyst consensus 103.91 CHF price target (11 covering analysts, Buy rating) — 31.7 percent upside. The valuation signal is fair. This is a quality-growth-at-a-reasonable-price thesis, not a deep-value cycle-bottom play. The setup is buying a healthy CDMO franchise in the lower third of its trading range while the capex cycle absorbs free cash flow.

The Siegfried family and the Berkshire Hathaway-style holding company Renova Group (Viktor Vekselberg vehicle, although sanctioned and the position is in legal limbo) historically controlled approximately 25 percent. Today the disclosed-shareholder structure is approximately: free-float 70 percent, BlackRock 4.9 percent, MFS International Value Fund 3.8 percent, Norges Bank 3.4 percent, Swiss Pension Fund Group 3.1 percent. The institutional book is dominated by European specialty-pharma and quality-growth investors — Pictet Asset Management, Lombard Odier, Schroders all hold positions.

Short interest is zero — there is no concentrated short. Smart-money buying has been steady in the 75 to 80 CHF range through Q1 2026; volume profile shows quality-growth fund accumulation rather than momentum-trade rotation. The CDMO peer-group multiple compression (Lonza at 22x forward, Catalent at 19x, WuXi Biologics at 25x discount due to US sanctions risk) has dragged Siegfried's multiple down with it; once the China-CDMO regulatory overhang clarifies and Big Pharma volume guidance for 2026 to 2027 lands, the peer-group re-rate could accelerate.

At 78.90 CHF Siegfried trades on 20.6x trailing P/E, 17.4x forward P/E, 2.6x sales, 3.1x book, and 12.9x EV/EBITDA. The metrics are fair-to-slightly-cheap for a high-quality CDMO with mid-teens earnings growth. The valuation signal is fair.

Three valuation paths. (1) Mean reversion to 200-day moving average of 81 CHF plus modest earnings growth — 6 percent total return; (2) Earnings growth to 5.40 CHF EPS in 2027 (Evionnaz at full run-rate) at 18x P/E — 97 CHF per share, 23 percent upside plus dividend; (3) Multiple expansion to peer-median Lonza-equivalent 22x P/E plus EPS to 5.40 — 119 CHF per share, 51 percent upside over 24 months. Analyst consensus 103.91 CHF aligns with the middle-to-upper path.

1. H1 2026 results (July 2026):

   Operating margin sustaining above 19 percent and Evionnaz facility contribution becoming visible in segment reporting. Either signal confirms the operating-leverage trajectory.

2. Eli Lilly capacity expansion announcement:

   Lilly has publicly indicated additional CDMO capacity contracting for Zepbound European market expansion. Any award announcement involving Siegfried would be a major catalyst.

3. Capital Markets Day Q4 2026:

   Management has not held a formal CMD since 2022. A refreshed medium-term framework with explicit 2028 to 2030 margin targets would unlock institutional re-rating.

Siegfried is the quality version of the GLP-1 supply-chain trade — direct exposure to one of the largest pharma platforms of the decade without the single-product binary risk of betting on Novo or Lilly stock. The CDMO industry structure is consolidated to a Big-Five (Lonza, Catalent, Patheon, Recipharm, Siegfried); each adds long-duration contracted revenue at premium margins. The capex cycle is a real near-term cost (negative FCF, leverage tick-up) but it is investing in the structural tailwind, not defending against decline.

I would size at 2 to 3 percent of portfolio for a 24 to 36 month horizon with a 65 CHF stop-loss (5 percent below the 52-week low). Upside scenarios cluster at 100 to 120 CHF; downside at 60 to 68. Asymmetry is approximately 3-to-1 favorable. The thesis is similar to Stevanato (GLP-1 supply chain) but with the operating-margin profile of a higher-margin Swiss specialty pharma. A good quality-growth long for portfolios that want pharma tailwinds without single-drug binary risk.